Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
NCT02625623
Completed
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2020
Locations: Rocky Mountain Cancer Centers 1800 Williams Street, Suite 100, Denver, Colorado +74 locations
Conditions: Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Register for Updates
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01412229
Completed
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2020
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +2 locations
Conditions: Head and Neck Cancer
Register for Updates
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
NCT02392507
Completed
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2020
Locations: Florida Hospital Cancer Institute, Orlando, Florida
Conditions: Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00026104
Completed
Randomized phase II trial to compare the effectiveness of gemcitabine, paclitaxel, and radiation therapy with or without tipifarnib in treating patients who have locally advanced pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining chemotherapy an... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/29/2020
Locations: Radiation Therapy Oncology Group, Philadelphia, Pennsylvania
Conditions: Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Register for Updates
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
NCT00506779
Terminated
Objectives: * To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma. * To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in this cohort of patients. * To determine the efficacy of imatinib mesylate and paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma whose tumor expresses either c-Kit, PD... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
10/26/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Uterine Cancer
Register for Updates
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT02730247
Completed
The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs. If they join this study, they would receive ramucirumab (Cyramza ®) in combination with nab-paclitaxel (Abraxane®). Ramucirumab given with nab-paclitaxel is considered an investigational drug combination to use in this type of cancer because giving these two drugs together has not been approved by any regulatory authority like the US Food... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2020
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Non-small Cell Lung Cancer
Register for Updates
Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer
NCT00006027
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor tissue. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without combination chemotherapy for endometrial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without combination chemotherapy following surgery in treating patients who have stage I or sta... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/21/2020
Locations: Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California +28 locations
Conditions: Endometrial Cancer
Register for Updates
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
NCT00030654
Completed
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy given at the same time as hormone therapy is more effective... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/21/2020
Locations: Foundation for Cancer Research and Education, Phoenix, Arizona +77 locations
Conditions: Prostate Cancer
Register for Updates
ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis
NCT04606342
Not Yet Recruiting
This is a dose-escalating phase I using a rolling 6 design and randomized phase II study of ATI-450 in combination with chemotherapy testing the hypothesis that the combination of chemotherapy (paclitaxel or capecitabine) and ATI-450 will improve progression-free survival and reduce bone turnover, improve patient bone density, improve patient quality of life, and improve clinical efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2020
Locations: Kansas University, Kansas City, Kansas +2 locations
Conditions: Breast Cancer, Cancer of Breast
Register for Updates
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
NCT00003930
Completed
RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2020
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +228 locations
Conditions: Bladder Cancer
Register for Updates
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
NCT00004054
Completed
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus radiation therapy is more effective with or without combination chemotherapy for prostate cancer. PURPOSE: Randomized... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/19/2020
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +53 locations
Conditions: Prostate Cancer
Register for Updates
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
NCT02597036
Completed
The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2020
Locations: SMO Sarah Cannon Research Inst., Nashville, Tennessee +4 locations
Conditions: Solid Tumors
Register for Updates